A cost-effectiveness analysis of levofloxacin and ceftriaxone-azithromycin antibiotic USE among adult community-acquired pneumonia patients in persahabatan hospital 2017
Abstract
ABSTRACT The current advancement in pharmacoepidemiology does not only analyze the use and effect of drugs in terms of its efficacy and safety, but also through the economic perspective. Antibiotic is one of the drugs that are widely used as a consequence of the abundance of infectious diseases, including pneumonia. This study aimed to analyze the cost-effectiveness between levofloxacin and ceftriaxone-azithromycin antibiotics as the most used drugs among pneumonia patients in Persahabatan Hospital in 2017. This study was an observational analytic study using a cross-sectional method in 19 patients. A total sampling method was used to collect the samples while parametric unpaired T-test test was used to analyze the data. There were not any differences in total cost (p=0.338) and length of stay (p=0.121) between patients administered with levofloxacin and ceftriaxone-azithromycin. Pharmacoeconomically, levofloxacin antibiotics are the most cost-effective according to the interpretation of the cost-effectiveness table. Levofloxacin remains as the best choice because its use is more practical than ceftriaxone-azithromycin drugs. Keywords: azithromycin; ceftriaxone; community-acquired pneumonia; levofloxacin; pharmacoeconomic
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 19 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.